{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:42:02Z","timestamp":1783611722225,"version":"3.55.0"},"reference-count":12,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Small cell lung cancer (SCLC) with ectopic adrenocorticotropic hormone (ACTH) syndrome and resultant hypercortisolism carries a poor prognosis with a short median survival and high incidence of infective complications. The combination of etoposide with either carboplatin or cisplatin is the current standard chemotherapy used for the management of SCLC. Etoposide is metabolised by cytochrome P450 3A4. Ketoconazole is an imidazole derivative possessing antifungal properties and also causes inhibition of adrenal corticosteroid and androgen production. There is an additional increased risk of toxicity due to a potential interaction between etoposide and ketoconazole, which is a strong inhibitor of cytochrome P450 3A4, and theoretically can lead to greater myelosuppression. Metyrapone can be a safe alternative in such settings.<\/jats:p>","DOI":"10.1136\/bcr.04.2010.2917","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T09:54:08Z","timestamp":1312538048000},"page":"bcr0420102917","source":"Crossref","is-referenced-by-count":5,"title":["Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide"],"prefix":"10.1136","volume":"2011","author":[{"given":"Shaikh Irfan","family":"Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Adnan","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsing","family":"Ladipeerla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2011,8,5]]},"reference":[{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.1992.10.1.21","article-title":"Cushing\u2019s syndrome associated with ectopic corticotrophin production and small-cell lung cancer","volume":"10","author":"Shepherd","year":"1992","journal-title":"J Clin Oncol"},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800315)45:6<1432::AID-CNCR2820450622>3.0.CO;2-Z"},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821115)50:10<2147::AID-CNCR2820501029>3.0.CO;2-M"},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.4","unstructured":"Bunn PA Ridgway EC . Paraneoplastic syndromes. In: De Vita V Hellman S Rosenberg SA , eds. Cancer Principles and Practice. Philadelphia, PA: Lippincott 1989:1898\u201340."},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410060054009"},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.6","unstructured":"Carroll TB Aron DC Findling JW . In: Gardner DG Shoback D , eds. Glucocorticoids and Adrenal Androgens. Greenspan\u2019s Basic & Clinical Endocrinology. Eighth edition. San Francisco, CA: McGraw-Hill 2007:346\u201389."},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.7","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1985.00360050119020"},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.8","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.44.512.485"},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.9","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0022-3565(24)37724-9","article-title":"A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes","volume":"286","author":"Kawashiro","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.10","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0022-3565(24)37724-9","article-title":"A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes","volume":"286","author":"Kawashiro","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.11","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.1992.10.10.1635","article-title":"Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance","volume":"10","author":"Lum","year":"1992","journal-title":"J Clin Oncol"},{"key":"2025082803205129000_2011.aug04_1.bcr0420102917.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0428-5"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.04.2010.2917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:21:00Z","timestamp":1756376460000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.04.2010.2917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,5]]},"references-count":12,"alternative-id":["10.1136\/bcr.04.2010.2917"],"URL":"https:\/\/doi.org\/10.1136\/bcr.04.2010.2917","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,5]]}}}